Loading...

SUVEN Suven Life Sciences Ltd Product Launches Announcement

Svn

SVN

Suven Life Sciences Ltd

(SUVEN)

2024 Announcement

Show Summary

Summary

Clinical Trial Update

Regulatory Compliance

Annual Compliance Report

Stock Options Granted

EGM Notice Published

Monitoring Agency Report

Financial Results

Preferential Issue

Regulatory Compliance

Tax Penalty Notice

Tax Demand Notice

Tax Demand Notice

Monitoring Agency Report

Financial Results Published

No Deviation Report

Phase-1 Trial Start

Compliance Certificate

Dividend Reminder

Rights Issue Report

Financial Results Published

Fund Utilization Update

Regulatory Filing

Positive Study Results

Positive Clinical Data

FDA Approval Received

Monitoring Agency Report

Financial Results Publication

Confirmation Statement

Certificate Submission

Newspaper Publication

Newspaper Advertisement

Compliance Report Submission

Monitoring Agency Report

Financial Results Publication

Deviation Statement

Managing Director Re-appoin...

Financial Results Announcement

Grant of Stock Options

Compliance Certificate Subm...

Compliance Certificate Subm...

Certificate Submission

Phase-2 Clinical Trial

Newspaper Publication

Un-audited Financial Results

Deviation in Utilization of...

Appointment and Retirement ...

Certificate under Regulatio...

Reminder to claim dividends...

Monitoring Agency Report

Newspaper Advertisement - F...

Statement of Deviation

Phase-2 Results

Certificate Submission

Financial Statements

Information Disclosure

Newspaper Advertisement

New Product Launches

Investor Meetings

Rights Offerings

Publication of Results

Related Party Transactions

Statement of Deviations or ...

External Links:

Data:

Suven Life Sciences has received FDA approval to initiate a Phase-1 clinical trial for its drug SUVN-I6107, aimed at treating dementia, with trial participants expected to enroll starting H2-2024.

AI Assistant

Suven Life Sciences Ltd

2024

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.